Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study

Adrienne Y. L. Chan, Andrew S. C. Yuen, Daniel H. T. Tsai, Wallis C. Y. Lau, Yogini H. Jani, Yingfen Hsia, David P. J. Osborn, Joseph F. Hayes, Frank M. C. Besag, Edward C. C. Lai, Li Wei, Katja Taxis, Ian C. K. Wong*, Kenneth K. C. Man*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Downloads (Pure)


Recent studies raised concerns about the increasing use of gabapentinoids in different countries. With their potential for misuse and addiction, understanding the global consumption of gabapentinoids will offer us a platform to examine the need for any interventional policies. This longitudinal trend study utilised pharmaceutical sales data from 65 countries and regions across the world to evaluate the global trends in gabapentinoid consumption between 2008-2018. The multinational average annual percentage change of gabapentinoid consumption was +17.20%, increased from 4.17 defined daily dose per ten thousand inhabitants per day (DDD/TID) in 2008 to 18.26 DDD/TID in 2018. High-income countries had the highest pooled gabapentinoid consumption rate (39.92 DDD/TID) in 2018, which was more than six times higher than the lower-middle income countries (6.11 DDD/TID). The study shows that despite differences in healthcare system and culture, a consistent increase in gabapentinoid consumption is observed worldwide, with high-income countries remaining the largest consumers.
Original languageEnglish
Article number5005
Number of pages11
JournalNature Communications
Publication statusPublished - 17 Aug 2023


Dive into the research topics of 'Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study'. Together they form a unique fingerprint.

Cite this